CA2763347C - Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) - Google Patents

Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) Download PDF

Info

Publication number
CA2763347C
CA2763347C CA2763347A CA2763347A CA2763347C CA 2763347 C CA2763347 C CA 2763347C CA 2763347 A CA2763347 A CA 2763347A CA 2763347 A CA2763347 A CA 2763347A CA 2763347 C CA2763347 C CA 2763347C
Authority
CA
Canada
Prior art keywords
coenzyme
cells
coq10
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2763347A
Other languages
English (en)
French (fr)
Other versions
CA2763347A1 (en
Inventor
Niven Rajin Narain
John Patrick Mccook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BERG LLC
Original Assignee
BERG LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BERG LLC filed Critical BERG LLC
Publication of CA2763347A1 publication Critical patent/CA2763347A1/en
Application granted granted Critical
Publication of CA2763347C publication Critical patent/CA2763347C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
CA2763347A 2009-05-11 2010-05-11 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) Active CA2763347C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US17724309P 2009-05-11 2009-05-11
US17724609P 2009-05-11 2009-05-11
US17724509P 2009-05-11 2009-05-11
US17724109P 2009-05-11 2009-05-11
US17724409P 2009-05-11 2009-05-11
US61/177,244 2009-05-11
US61/177,241 2009-05-11
US61/177,245 2009-05-11
US61/177,246 2009-05-11
US61/177,243 2009-05-11
PCT/US2010/034453 WO2010132507A2 (en) 2009-05-11 2010-05-11 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)

Publications (2)

Publication Number Publication Date
CA2763347A1 CA2763347A1 (en) 2010-11-18
CA2763347C true CA2763347C (en) 2021-11-23

Family

ID=43085533

Family Applications (5)

Application Number Title Priority Date Filing Date
CA2763347A Active CA2763347C (en) 2009-05-11 2010-05-11 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
CA2763325A Abandoned CA2763325A1 (en) 2009-05-11 2010-05-11 Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2763336A Expired - Fee Related CA2763336C (en) 2009-05-11 2010-05-11 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2762213A Abandoned CA2762213A1 (en) 2009-05-11 2010-05-11 Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2761717A Abandoned CA2761717A1 (en) 2009-05-11 2010-05-11 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers

Family Applications After (4)

Application Number Title Priority Date Filing Date
CA2763325A Abandoned CA2763325A1 (en) 2009-05-11 2010-05-11 Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2763336A Expired - Fee Related CA2763336C (en) 2009-05-11 2010-05-11 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2762213A Abandoned CA2762213A1 (en) 2009-05-11 2010-05-11 Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2761717A Abandoned CA2761717A1 (en) 2009-05-11 2010-05-11 Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers

Country Status (13)

Country Link
US (15) US10519504B2 (en17)
EP (5) EP2429511B1 (en17)
JP (13) JP6081195B2 (en17)
KR (7) KR101829201B1 (en17)
CN (7) CN104825429A (en17)
AU (9) AU2010247761A1 (en17)
BR (5) BRPI1010827A2 (en17)
CA (5) CA2763347C (en17)
EA (5) EA201101522A1 (en17)
IL (5) IL216296B (en17)
MX (6) MX2011011958A (en17)
SG (10) SG175993A1 (en17)
WO (5) WO2010132479A2 (en17)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2755840T3 (es) * 2007-03-22 2020-04-23 Berg Llc Formulaciones tópicas que tienen biodisponibilidad aumentada
SG175993A1 (en) 2009-05-11 2011-12-29 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
MY163995A (en) 2010-03-12 2017-11-15 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EP2595616B1 (en) * 2010-06-30 2016-04-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
SG182016A1 (en) * 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
WO2012087278A1 (en) * 2010-12-20 2012-06-28 Tebbi Cameron K Methods of detecting leukemia/ lymphoma and induction of the same
US9783785B2 (en) 2010-12-20 2017-10-10 Cameron K. Tebbi Screening methods for detection of susceptibility to leukemia and lymphomas
AU2012205337B2 (en) * 2011-01-13 2017-04-13 Expression Pathology, Inc. Bcl-2-like protein 11 SRM/MRM assay
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
MY164530A (en) 2011-03-02 2017-12-29 Berg Llc Interrogatory cell-based assays and uses thereof
RU2453849C1 (ru) * 2011-03-11 2012-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ определения метаболитов углеводного обмена в биологических тканях
WO2012138765A1 (en) * 2011-04-04 2012-10-11 Berg Pharma Llc Methods of treating central nervous system tumors
EP2720689A4 (en) * 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATÉCHOL DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS DISEASES
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
CN102453769A (zh) * 2011-12-27 2012-05-16 芮屈生物技术（上海）有限公司 白血病病变前期mRNA水平原位杂交检测试剂盒及检测方法和应用
US9399035B2 (en) * 2012-03-06 2016-07-26 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
KR20200105524A (ko) * 2012-04-02 2020-09-07 버그 엘엘씨 조사적 세포 기반 분석 및 이의 사용
JP6352905B2 (ja) 2012-06-01 2018-07-04 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療
CA2883810C (en) * 2012-09-06 2017-10-31 Hitachi Chemical Co., Ltd. Methods for assessment of peptide-specific immunity
KR102198633B1 (ko) 2012-09-19 2021-01-05 그레스포 에이비 뇌기능 향상용 조성물
CN110151591A (zh) 2012-10-09 2019-08-23 宝洁公司 鉴定协同化妆品组合的方法
JP6194003B2 (ja) 2012-10-09 2017-09-06 ザ プロクター アンド ギャンブル カンパニー 有益剤及びこれを含む組成物の特定又は評価方法
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
WO2014144346A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of inhibitors of mtor to improve vascular functions in apoe4 carriers
WO2014152086A1 (en) * 2013-03-19 2014-09-25 The Procter & Gamble Company Method of measuring the metabolic indicators of hair follicles
SG10201903112WA (en) * 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
WO2014181968A1 (ko) * 2013-05-09 2014-11-13 가톨릭대학교 산학협력단 메트포민과 코엔자임 q10을 유효성분으로 함유하는 면역 질환의 예방 또는 치료용 조성물
WO2014210389A1 (en) * 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore
EA034143B1 (ru) 2013-09-04 2020-01-09 Берг Ллк Способы лечения рака непрерывной инфузией кофермента q10
CN103585619A (zh) * 2013-10-31 2014-02-19 浙江大学 Dj-1蛋白在制备骨肉瘤诊断和治疗产品中的应用
CR20160289A (es) 2013-11-22 2016-09-27 Pharmakea Inc Compuestos de inhibidor de autotaxina
US20160310572A1 (en) * 2013-12-02 2016-10-27 Wayne State University Compositions and methods to diagnose diabetes and/or to treat negative effects of diabetes
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US20160341739A1 (en) * 2014-01-15 2016-11-24 The Regents Of The University Of California Metabolic screening for gestational diabetes
CA2945027C (en) * 2014-04-07 2023-10-31 Memorial Sloan Kettering Cancer Center Modulating cell proliferation and pluripotency
JP6487031B2 (ja) * 2014-04-17 2019-03-20 イミューノメット セラピューティクス インコーポレイテッド グアニジン化合物、及びその用途
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
EP3550306B1 (en) * 2014-08-26 2021-03-03 Keio University Anti-cancer agent sensitivity-determining marker
EP3191975A4 (en) 2014-09-11 2018-04-18 Berg LLC Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
AU2016268250B2 (en) 2015-05-27 2020-08-27 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
EP3544993A1 (en) * 2016-11-25 2019-10-02 Koninklijke Philips N.V. Method to distinguish tumor suppressive foxo activity from oxidative stress
US20210130291A1 (en) 2016-12-22 2021-05-06 The National Institute for Biotechnology in the Negev Ltd. Methods for treating diabetes using vdac1 inhibitors
AU2017381697B2 (en) 2016-12-23 2020-12-24 Keio University Compositions and methods for the induction of CD8+ T-cells
CN110769818A (zh) 2017-05-17 2020-02-07 博格有限责任公司 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途
CN113683700B (zh) * 2017-06-22 2023-05-02 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
JP7209951B2 (ja) * 2017-10-30 2023-01-23 日本メナード化粧品株式会社 白髪予防及び改善剤
SG11202004384YA (en) 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
AU2019217041B2 (en) * 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
SG11202102204PA (en) 2018-09-25 2021-04-29 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CN113646432A (zh) 2019-01-23 2021-11-12 雷杰纳荣制药公司 用血管生成素样7(angptl7)抑制剂治疗眼科疾病
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
WO2021102356A1 (en) 2019-11-20 2021-05-27 Berg Llc Combination therapy of a coenzyme q10 compound and radiation therapy for treatment of glioma
JP2021084891A (ja) * 2019-11-28 2021-06-03 株式会社ノエビア 抗老化剤
CN112924681B (zh) * 2019-12-05 2023-01-17 张曼 尿液krt10蛋白及其多肽片段在正常妊娠中的应用
KR102383788B1 (ko) * 2020-06-12 2022-04-05 이화여자대학교 산학협력단 신체적 스트레스 상태를 평가하는 방법
EP4175978A4 (en) * 2020-07-02 2024-06-26 Ponce de Leon Health Designated Activity Company COMPOSITIONS AND METHODS FOR TREATING CRP-MEDIATED DISEASES
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
IL303536A (en) 2020-12-23 2023-08-01 Regeneron Pharma Treatment of liver diseases with DFFA-like activator inhibitors causing B-cell death
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN114306608B (zh) * 2022-01-04 2024-01-16 上海科技大学 一类适应低氧或缺氧微环境的肿瘤的治疗靶点及其应用
CN117347643B (zh) * 2023-12-05 2024-02-06 成都泰莱生物科技有限公司 用于判断肺部结节良恶性的代谢标志物组合及其筛选方法和应用

Family Cites Families (392)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) * 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
JPS5775916A (en) 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS58113127A (ja) 1981-12-28 1983-07-05 Ajinomoto Co Inc ユビデカレノン含有水性液
IT1157269B (it) * 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4833128A (en) 1984-12-28 1989-05-23 Neil Solomon Dietary supplement
US4824669A (en) 1985-04-11 1989-04-25 Board Of Regents, The University Of Texas System Formulations of coenzyme Q10 for intravenous use
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JPS62123113A (ja) 1985-11-22 1987-06-04 Green Cross Corp:The ユビデカレノン含有脂肪乳剤
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
JP2600726B2 (ja) 1987-11-30 1997-04-16 大正製薬株式会社 微粒子脂肪乳剤
GB8811410D0 (en) 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
JP2828655B2 (ja) 1989-04-14 1998-11-25 エーザイ株式会社 脂溶性薬物含有水性液
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5962243A (en) 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
ATE117665T1 (de) 1990-11-14 1995-02-15 Oreal Amphiphile, nichtionische derivate des glycerins sowie die entsprechenden zwischenprodukte, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5378461A (en) 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US6461593B1 (en) 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
WO1993016704A1 (en) 1992-02-24 1993-09-02 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
US6093706A (en) 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
FR2697841B1 (fr) 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
WO1994020508A1 (en) 1993-03-08 1994-09-15 Eisai Co., Ltd. Phosphonic acid derivatives
ATE166573T1 (de) 1993-03-24 1998-06-15 Ciba Geigy Ag Verfahren zur herstellung einer liposomendispersion im hochdruckbereich
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (de) * 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
US20020049422A1 (en) 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
CA2207093A1 (en) 1994-12-06 1996-06-13 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
DE19537027A1 (de) 1995-10-05 1997-04-10 Beiersdorf Ag Hautpflegemittel für alte Haut
AU730969B2 (en) 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (de) * 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
ATE201988T1 (de) 1997-02-11 2001-06-15 Mse Pharmazeutika Gmbh Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4- benzochinon
EP1007018B1 (de) * 1997-02-12 2003-10-08 MSE Pharmazeutika GmbH Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
JP2001514209A (ja) 1997-09-04 2001-09-11 バイオゾーン ラボラトリーズ，インコーポレイテッド 経口リポソーム送達系
AU1289899A (en) 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) * 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
EP1065931A4 (en) 1998-04-02 2006-10-11 Avicena Group Inc COMPOSITIONS CONTAINING CREATINE COMBINED WITH A SECOND AGENT
CA2630341C (en) 1998-04-14 2011-07-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing isoprenoid compounds by microorganisms
US6503523B2 (en) 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
WO1999065469A2 (en) 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
DE19828081C2 (de) 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W/O-Emulsionsgrundlagen
DE59905858D1 (de) 1998-07-16 2003-07-10 Cognis Deutschland Gmbh Verwendung von pit-emulsionen
US7635722B1 (en) 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
AU5334899A (en) 1998-08-04 2000-02-28 Kosbab, John V. Nutrient and therapeutic compositions for the treatment of cancer
JP2002526446A (ja) * 1998-09-23 2002-08-20 リサーチ ディベロップメント ファンデーション トロフェロール、トコトリエノール、その他のクロマン及び側鎖誘導体、並びにそれらの利用
US6048886A (en) 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US20050019268A1 (en) 1999-02-11 2005-01-27 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
ES2247749T3 (es) * 1999-07-02 2006-03-01 Cognis Ip Management Gmbh Microcapsulas iii.
US20030104080A1 (en) 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US6630160B1 (en) 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
WO2001026670A1 (fr) 1999-10-14 2001-04-19 The Nisshin Oil Mills, Ltd. Agents de soin de la peau, agents anti-ages pour la peau, agents de blanchiment de la peau et preparations pour la peau, a usage externe
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US20020049176A1 (en) 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
US20030091518A1 (en) 1999-12-20 2003-05-15 Gilles Pauly Cosmetic and/or pharmaceutical preparations
AUPQ515000A0 (en) 2000-01-19 2000-02-10 Grigg, Geoffrey Walter Treatment of uv induced immunosuppression
WO2001056562A1 (fr) 2000-02-04 2001-08-09 Takeda Chemical Industries, Ltd. Compositions d'emulsions stables
NZ509803A (en) 2000-02-09 2001-08-31 Paul A Treatment of fibromyalgia with ubiquinone 10 and succinic acid
FR2804864B1 (fr) 2000-02-11 2003-04-04 Serobiologiques Lab Sa Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
ATE479419T1 (de) 2000-02-17 2010-09-15 Basf Se Wässrige dispersion wasserunlöslicher organischer uv-filtersubstanzen
DE10007322A1 (de) * 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Perlglanzmittel
FR2805464B1 (fr) 2000-02-25 2003-02-14 Serobiologiques Lab Sa Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis
DE10009996B4 (de) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
PL363113A1 (en) 2000-03-27 2004-11-15 Schott Glas New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
US6447760B2 (en) 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
WO2001085156A1 (fr) 2000-05-09 2001-11-15 Kaneka Corporation Compositions dermiques ayant la coenzyme q comme principe actif
US6468552B1 (en) 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
SE0002189D0 (sv) * 2000-06-09 2000-06-09 Metcon Medicin Ab New method and assay
DE10031703A1 (de) * 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
EP1170015A1 (de) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Verwendung von Extrakten des Pilzes Grifola frondosa
DE10033022A1 (de) * 2000-07-07 2002-01-17 Cognis Deutschland Gmbh Aerosole
US20030012825A1 (en) 2000-07-10 2003-01-16 Charles Kapper Metallized molecule therapies
US6465517B1 (en) 2000-07-11 2002-10-15 N.V. Nutricia Composition for the treatment of migraine
DE10034619A1 (de) * 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
DE10036655A1 (de) 2000-07-26 2002-02-07 Basf Ag Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10036799A1 (de) 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20020045230A1 (en) 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
FR2813195B1 (fr) 2000-08-29 2003-04-04 Serobiologiques Lab Sa Utilisation d'extraits de la plante cassia alata dans des produits de soin
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10048260A1 (de) 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10053328A1 (de) 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
IT1317938B1 (it) 2000-11-17 2003-07-15 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese
US20070003536A1 (en) * 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
JP2004515508A (ja) 2000-12-16 2004-05-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 化合物の健康促進組成物
DE10064818A1 (de) 2000-12-22 2002-06-27 Basf Ag Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (fr) 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection
WO2002056823A2 (en) 2001-01-18 2002-07-25 Arnold Hoffman Redox therapy for tumors
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
NL1017205C2 (nl) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinale en cosmetische toepassing van hop en co-enzym Q10.
ITRM20010044A1 (it) 2001-01-29 2002-07-29 Sigma Tau Healthscience Spa Integratore alimentare ad effetto dimagrante.
IL157145A0 (en) 2001-01-31 2004-02-08 Idec Pharma Corp Use of dc23 antagonists for the treatment of neoplastic disorders
ITMI20010204A1 (it) 2001-02-02 2002-08-02 Hunza Di Marazzita Maria Carme Specialita' terapeutiche dotate di attivita' antiossidante ed in grado di controllare l'eccesso del peso corporeo
FR2821624B1 (fr) 2001-03-01 2004-01-02 Sod Conseils Rech Applic Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses
CA2439078C (en) 2001-03-09 2009-08-25 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
DE10113050A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden
DE10113053A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden
DE10113046A1 (de) 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
EP1243252B1 (fr) 2001-03-23 2006-05-24 L'oreal Composition pour le peau, contenant des fibres et des ubiquinones
US20030031688A1 (en) * 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) * 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
US6469061B1 (en) 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
DE10118269A1 (de) 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6686485B2 (en) * 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US20040049022A1 (en) 2001-04-24 2004-03-11 Nyce Jonathan W. Composition & methods for treatment and screening
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (ja) 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
AU2002309038B2 (en) 2001-05-10 2007-05-17 Kaneka Corporation Compositions for transmucosal administration containing coenzyme Q as the active ingredient
DE10123771B4 (de) 2001-05-16 2019-01-10 Beiersdorf Ag Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
EP1260212A1 (de) 2001-05-21 2002-11-27 Cognis France S.A. Kosmetische Mittel
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
PT1390025E (pt) 2001-05-30 2005-08-31 Laxdale Ltd Utilizacao de coenzima q (ubiquinona) e acido eicosapentaenoico (epa) para o tratamento de linfoma nao de hodgkin e de distubios psiquiatricos ou neurologicos
US20030138792A1 (en) * 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
EP1262167A1 (de) 2001-06-01 2002-12-04 Cognis France S.A. Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen
US6696060B2 (en) 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US6506915B1 (en) 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (fr) 2001-06-15 2004-06-11 Cognis France Sa Melanges de tensioactifs
SE0102380D0 (sv) 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
DE10133198A1 (de) 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
EP1414841B1 (en) 2001-07-10 2012-11-14 Lakewood-Amedex, Inc Oligonucleotide-containing pharmacological compositions and their use
JP2003020495A (ja) 2001-07-10 2003-01-24 Cognis Japan Ltd 油脂組成物
CH695085A5 (de) * 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
TWI235146B (en) * 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
FR2827603B1 (fr) 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
DE60222670T3 (de) 2001-07-27 2011-08-18 N.V. Nutricia Orale zusammesetzung zur vorbeugung oder behandlung von sepsis
EP1281392A1 (de) 2001-08-02 2003-02-05 Cognis France S.A. Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte
DE10139580A1 (de) * 2001-08-10 2003-02-20 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren
US6503506B1 (en) 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
DE10143962A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143963A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143964A1 (de) 2001-09-07 2003-03-27 Basf Ag Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon
WO2003024417A1 (en) 2001-09-18 2003-03-27 Ciba Specialty Chemicals Holding Inc. Use of guaiol for treating the skin
DE10150725A1 (de) * 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
AU2002335040A1 (en) 2001-10-16 2003-04-28 Atherogenics, Inc. Protection against oxidative stress and inflammation by a cytoprotective response element
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US6723527B2 (en) 2001-10-26 2004-04-20 Board Of Regents, The University Of Texas System Methods for determining toxicity reversing agents
US20060039956A1 (en) 2001-10-26 2006-02-23 Hermann Hensen Impregnating solution for cosmetic cloths
ES2320980T3 (es) 2001-11-03 2009-06-01 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030105027A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US20030118536A1 (en) 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US7435725B2 (en) 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US7527932B2 (en) * 2001-11-09 2009-05-05 Medstar Research Institute, Inc. Method of using physiological markers to estimate cardiovascular risk
DE10155769A1 (de) 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10160682A1 (de) * 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Emollients und kosmetische Zusammensetzungen
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162351A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10162026A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Perlglanzkonzentrate
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TWI305547B (en) 2001-12-27 2009-01-21 Kaneka Corp Processes for producing coenzyme q10
US20030129253A1 (en) * 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
CA2471712A1 (en) 2002-01-18 2003-07-24 Basf Aktiengesellschaft Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
JP2005522421A (ja) 2002-01-31 2005-07-28 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド ミクロ顔料混合物
AU2003206825B8 (en) * 2002-02-12 2008-03-20 Dsm Ip Assets B.V. Sunscreen compositions as well as dihydropyridines and dihydropyranes
WO2003068008A1 (en) 2002-02-14 2003-08-21 Dsm Ip Assets B.V. Water-dispersible coenzyme q10 dry powders
EP1340486A1 (de) 2002-03-01 2003-09-03 Cognis France S.A. Verwendung von Zuckerestern
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
DE10254315A1 (de) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Emollients und kosmetische Zubereitungen
WO2003078456A2 (en) 2002-03-20 2003-09-25 Syddansk Universitet Human diabetes-mediating proteins
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
DE10212528A1 (de) * 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Ölphasen für kosmetische Mittel
DE10213957A1 (de) * 2002-03-28 2003-10-09 Beiersdorf Ag Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
US7811594B2 (en) 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
WO2003087768A2 (en) * 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
DE10217474A1 (de) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sonnenschutzemulsion mit Schaumspender
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
CN100522245C (zh) 2002-05-23 2009-08-05 Umd公司 用于穿粘膜的药物输送和冷冻保护的组合物
DE10223486A1 (de) 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
EP1371355B1 (en) 2002-06-03 2006-08-02 Ciba SC Holding AG UV-protection formulations
DE10226018A1 (de) 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Zubereitungen mit konjugiertem Linolalkohol
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
AU2003246592A1 (en) 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
EP1545509A4 (en) 2002-09-25 2008-10-22 Univ Rochester CASPASE HEMMER AS CANCER
US6953786B2 (en) 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
EP1421929A3 (de) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients und kosmetische Zubereitungen
DE10256881A1 (de) 2002-12-05 2004-06-24 Beiersdorf Ag Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
WO2004055181A1 (en) 2002-12-16 2004-07-01 Garvan Institute Of Medical Research Methods of treatment of feeding disorders or disorders of glucose uptake and for modifying metabolism and identifying therapeutic reagents therefor
EP1587955A4 (en) 2002-12-24 2007-03-14 Biosite Inc DIFFERENTIAL DIAGNOSTIC MARKERS AND METHODS OF USE
ES2526695T3 (es) * 2003-01-02 2015-01-14 Gerard M. Housey Moduladores de IRS
US20090036516A1 (en) 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2004064797A1 (en) 2003-01-20 2004-08-05 Ciba Specialty Chemicals Holding, Inc. Triazine derivatives as uv absorbers
AU2003277903A1 (en) 2003-02-03 2004-08-30 Dsm Ip Assets B.V. Novel stabilized cinnamic ester sunscreen compositions
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (zh) 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
ES2435512T3 (es) 2003-03-24 2013-12-20 Basf Se Derivados simétricos de triazina
ES2712944T3 (es) 2003-04-08 2019-05-16 Barrie Tan Composiciones de extracto de achiote, que incluyen geranilgeranioles para su uso en la reducción del nivel de triglicéridos en sangre
US20050037102A1 (en) 2003-07-18 2005-02-17 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
JP2004321171A (ja) * 2003-04-11 2004-11-18 Fancl Corp 飲食品
EP1473043A1 (en) 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
JP2004345988A (ja) 2003-05-21 2004-12-09 Eisai Co Ltd リボフラビン系化合物を含む医薬組成物
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20040253323A1 (en) 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
KR20060082791A (ko) 2003-06-25 2006-07-19 찰스 에르윈 코엔자임 ｑ10의 전달을 증가시키기 위한 화학적 배합물 및방법
US20050026848A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US8802161B2 (en) 2003-08-02 2014-08-12 Florida Agricultural And Mechanical University Herbal composition and method of use for the treatment of cancer
US20070248693A1 (en) 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
JP2007503418A (ja) 2003-08-27 2007-02-22 バイヤースドルフ・アクチエンゲゼルシヤフト 局所使用中に個別には感知不能になる外皮を有するカプセル
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
JP2007507432A (ja) 2003-10-02 2007-03-29 セムバイオシス ジェネティクス インコーポレイテッド 活性成分を含む油体を調製するための方法
DE10347218A1 (de) 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sonnenschutzmittel
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
DE10347940A1 (de) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Selbstemulgierende Zubereitungen
US20070243180A1 (en) 2003-10-31 2007-10-18 Hozumi Tanaka Composition Containing Reduced Coenzyme Q
ES2334797T3 (es) 2003-11-05 2010-03-16 Dsm Ip Assets B.V. Composicion protectora de la luz con una cantidad total reducida de filtro uv que contiene un filtro uv a base de polisiloxano.
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
WO2005048925A2 (en) 2003-11-14 2005-06-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
DE20320413U1 (de) 2003-11-17 2004-08-26 Beiersdorf Ag Kosmetikum mit empfindlichen Inhaltsstoffen
US20050118235A1 (en) 2003-12-02 2005-06-02 Shiguang Yu Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake
BRPI0417723A (pt) 2003-12-18 2007-04-03 Nestec Sa composição para melhorar a saúde da pele, cabelo e tegumento contendo flavanonas
JP4742526B2 (ja) * 2003-12-26 2011-08-10 シンフォニアテクノロジー株式会社 Ｉｃチップ実装体の製造方法及び製造装置
CA2553690C (en) 2004-01-22 2016-05-24 Sung Lan Hsia Topical co-enzyme q10 formulations and methods of use
US20050226947A1 (en) * 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
JP2007523156A (ja) * 2004-02-19 2007-08-16 ケマファー インコーポレイティッド 皮膚状態の処置用の局所製剤
EP1718163A1 (en) 2004-02-23 2006-11-08 The Texas A&M University System Antioxidant compositions and methods of use thereof
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20050202521A1 (en) 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
DE102004014615A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere
EP1734915A2 (en) * 2004-04-06 2006-12-27 Basf Aktiengesellschaft COSMETIC FORMULATIONS COMPRISING ZnO NANOPARTICLES
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7723569B2 (en) * 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
IL161899A0 (en) 2004-05-10 2005-11-20 Hoffman Arnold Kit for treatment of cancer
JP2005323573A (ja) * 2004-05-17 2005-11-24 Sumitomo Pharmaceut Co Ltd 遺伝子発現データ解析方法および、疾患マーカー遺伝子の選抜法とその利用
RU2375053C2 (ru) 2004-05-18 2009-12-10 Кемийски Инштитут Новая водорастворимая форма коэнзима q10 в форме комплекса включения с бета-циклодекстрином, способ ее получения и ее применение
NZ551366A (en) 2004-05-24 2009-01-31 Basf Ag Keratin-binding polypeptides
KR20050112942A (ko) 2004-05-28 2005-12-01 주식회사 뉴트렉스테크놀러지 비만 억제용 조성물
WO2005123075A2 (en) 2004-06-08 2005-12-29 University Of Florida Research Foundation, Inc. Controlling angiogenesis with anabaseine analogs
WO2006009825A1 (en) 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
ATE415976T1 (de) * 2004-06-18 2008-12-15 Symrise Gmbh & Co Kg Brombeerextrakt
CA2571457A1 (en) * 2004-06-21 2006-01-26 Hutchison Medipharma Enterprises Limited Cancer chemotherapy
ES2380940T3 (es) 2004-06-28 2012-05-21 Dsm Ip Assets B.V. Composiciones cosméticas que contienen hidrolizados de proteína
SG156613A1 (en) 2004-07-13 2009-11-26 Oridis Biomed Forschungs Und E Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
US20060069068A1 (en) 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by pathological calcification
EP1771185A4 (en) 2004-07-28 2009-09-23 Raymond M Pleva COMPOSITION OF EYE AND FRUIT OIL
JP2006070016A (ja) 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物
WO2006017494A2 (en) * 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
EP2377532A1 (en) 2004-08-18 2011-10-19 Ace ApS Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders
US20060041017A1 (en) 2004-08-20 2006-02-23 Chopra Raj K Synergistic conjugated linoleic acid (CLA) and carnitine combination
US20060051462A1 (en) * 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
CN101102768A (zh) * 2004-09-17 2008-01-09 中国医学科学院医药生物技术研究所 治疗高脂血症的方法和组合物
US20060062755A1 (en) 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
JP5093998B2 (ja) 2004-09-22 2012-12-12 大塚製薬株式会社 色素沈着予防又は改善剤
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
CA2581816A1 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
US20060120997A1 (en) 2004-10-29 2006-06-08 Biomune, Inc. Cancer therapeutic compositions
JP2008518988A (ja) 2004-11-02 2008-06-05 ディーエスエム アイピー アセッツ ビー．ブイ． Ｕｖ−日焼け止め調製物のための添加剤
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
AU2004326297B2 (en) * 2004-11-16 2008-08-07 Bioavailability, Inc. High concentration self-microemulsifying coenzyme Q10 preparations for nutritional use
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
CN101099084A (zh) * 2004-12-14 2008-01-02 弗·哈夫曼-拉罗切有限公司 作为胰岛素耐受性的靶标/标记的cd99
WO2006063402A1 (en) 2004-12-16 2006-06-22 Melvin Mackenzie Stewart Therapeutic compositions based on extracts of plants from the genus plumeria (frangipani)
NO20045674D0 (no) * 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
DE102005007980A1 (de) 2005-02-22 2006-02-23 Clariant Gmbh Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse
JPWO2006103750A1 (ja) 2005-03-29 2008-09-04 日本ハム株式会社 肥満改善用組成物、機能性食品及び医薬用組成物
CA2603403A1 (en) 2005-04-01 2006-10-12 Zymes, Llc Skin enrichment using coq10 as the delivery system
CN1853507A (zh) 2005-04-28 2006-11-01 尚宝虎 一种没有副作用的可用于饮料和固体口服制剂或食品添加的减肥新组方
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
WO2007014392A2 (en) 2005-07-28 2007-02-01 Isp Investments Inc. Benzoquinones of enhanced bioavailability
EP1908459A4 (en) * 2005-07-28 2010-07-14 Kaneka Corp COMPOSITION PREVENTING CANCER
US20070053985A1 (en) 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
CN1928556A (zh) * 2005-09-05 2007-03-14 中国医学科学院基础医学研究所 中国人2型糖尿病血清标志物的检测试剂盒
US20070071779A1 (en) 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
EP1876448A1 (en) * 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US20070092469A1 (en) * 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9034316B2 (en) 2006-10-24 2015-05-19 Amorcyte, Llc Infarct area perfusion-improving compositions and methods of vascular injury repair
US9265792B2 (en) * 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
WO2007102861A2 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
JP2007176804A (ja) * 2005-12-27 2007-07-12 Ｚｍｃ−Ｋｏｕｇｅｎ株式会社 痩身作用を有する医薬又は健康食品
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
CA2642342A1 (en) * 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers
US20070203091A1 (en) 2006-02-28 2007-08-30 Eliezer Rapaport Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging
WO2007104173A2 (de) 2006-03-10 2007-09-20 Laboswiss Ag Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
US8030013B2 (en) 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
TW200808344A (en) 2006-04-28 2008-02-16 Kaneka Corp Stabilization method of reduced coenzyme Q10
EP2025662A4 (en) 2006-04-28 2011-07-27 Kaneka Corp PROCESS FOR PURIFYING REDUCED COENZYME Q10
EP2073819B1 (en) * 2006-05-02 2016-12-28 University of Miami Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
US20090191575A1 (en) 2006-06-05 2009-07-30 Makoto Watanabe Tumor marker and method for determination of the occurrence of cancerous disease
US20080020022A1 (en) 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP2123266B1 (en) 2006-12-06 2014-01-15 Kaneka Corporation Cancer therapeutic agent and anti-carcinogenic agent
CN101015524B (zh) * 2007-02-15 2011-09-14 沈阳药科大学 辅酶q10口服乳剂及其制备方法
ES2755840T3 (es) * 2007-03-22 2020-04-23 Berg Llc Formulaciones tópicas que tienen biodisponibilidad aumentada
WO2008156654A2 (en) * 2007-06-15 2008-12-24 Massachusetts Institute Of Technology Cytoskeleton modulators for treating metabolic disorders
US20090005398A1 (en) 2007-06-27 2009-01-01 Mohammed Dar Methods For The Treatment of Central Nervous System Tumors
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
KR100849537B1 (ko) 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
ES2443540T3 (es) 2007-07-17 2014-02-19 Metabolon, Inc. Biomarcadores para pre-diabetes y métodos que usan los mismos
CN101091890A (zh) 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
RU2345367C1 (ru) 2007-08-22 2009-01-27 Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) Способ прогнозирования тяжести течения и эффективности лечения лимфом
JP2009050168A (ja) * 2007-08-23 2009-03-12 Tsujido Kagaku Kk 食品組成物
JP2010540498A (ja) 2007-09-28 2010-12-24 ウニヴェルズィテーツシュピタール バーゼル 癌の治療のための免疫リポソーム
JP2009096757A (ja) * 2007-10-17 2009-05-07 Tsujido Kagaku Kk 脂肪代謝抑制剤
JP5767812B2 (ja) 2007-12-06 2015-08-19 バーグ リミテッド ライアビリティ カンパニー 生物学的利用率が向上した吸入可能な組成物
WO2009126764A1 (en) * 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
JP5945096B2 (ja) 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
DE102008060773A1 (de) 2008-12-05 2010-06-10 Sartorius Stedim Biotech Gmbh Verschluss für einen Behälter
US8247435B2 (en) 2009-02-19 2012-08-21 Thornthwaite Jerry T Formulations for treating human and animal diseases
SG175993A1 (en) 2009-05-11 2011-12-29 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US20110064747A1 (en) 2009-08-25 2011-03-17 Rangaprasad Sarangarajan Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
US8506954B2 (en) 2009-12-01 2013-08-13 The Board Of Trustees Of The Leland Stanford Junior University Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy
MY163995A (en) 2010-03-12 2017-11-15 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
KR20220000943A (ko) 2010-07-19 2022-01-04 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
US9125835B2 (en) 2010-11-12 2015-09-08 Rutgers, The State University Of New Jersey Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
WO2012138765A1 (en) 2011-04-04 2012-10-11 Berg Pharma Llc Methods of treating central nervous system tumors
JP6352905B2 (ja) 2012-06-01 2018-07-04 バーグ エルエルシー コエンザイムｑ１０を用いた固形腫瘍の治療
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
EA034143B1 (ru) 2013-09-04 2020-01-09 Берг Ллк Способы лечения рака непрерывной инфузией кофермента q10
JP6398212B2 (ja) 2014-02-12 2018-10-03 株式会社Ihi 軸受構造、および、過給機
JP2017530130A (ja) 2014-10-03 2017-10-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用
CA2965034C (en) 2014-10-24 2023-05-02 Astrazeneca Ab Combination of an immunomodulatory agent and an antisense oligonucleotide
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2018018018A1 (en) 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators

Also Published As

Publication number Publication date
SG175996A1 (en) 2011-12-29
AU2010247750A1 (en) 2011-12-15
WO2010132479A2 (en) 2010-11-18
CN102481269B (zh) 2015-10-07
BRPI1010576A2 (pt) 2016-03-15
EP2429511A4 (en) 2013-08-28
KR20120034647A (ko) 2012-04-12
JP2012526828A (ja) 2012-11-01
US10351915B2 (en) 2019-07-16
US20210002725A1 (en) 2021-01-07
AU2010247800A1 (en) 2011-12-15
EA023913B1 (ru) 2016-07-29
US11028446B2 (en) 2021-06-08
MX2011011940A (es) 2012-06-25
BRPI1010827A2 (pt) 2019-09-24
KR20180018833A (ko) 2018-02-21
US20190010554A1 (en) 2019-01-10
US10519504B2 (en) 2019-12-31
SG10201402287TA (en) 2014-07-30
CN102481269A (zh) 2012-05-30
EA201101521A1 (ru) 2012-09-28
MX2011011949A (es) 2012-02-13
IL216296A0 (en) 2012-01-31
KR20120088555A (ko) 2012-08-08
SG10201402288RA (en) 2014-07-30
JP2016023190A (ja) 2016-02-08
US9896731B2 (en) 2018-02-20
MX357528B (es) 2018-07-13
BRPI1011025A8 (pt) 2016-07-19
EP2429512A4 (en) 2013-07-31
AU2016222422A1 (en) 2016-09-22
CA2763336C (en) 2018-10-30
WO2010132486A2 (en) 2010-11-18
US20170137879A1 (en) 2017-05-18
EP2429513A2 (en) 2012-03-21
US20110123986A1 (en) 2011-05-26
EP2430194A2 (en) 2012-03-21
MX345044B (es) 2017-01-16
KR20120034649A (ko) 2012-04-12
KR20120060945A (ko) 2012-06-12
CN102481270A (zh) 2012-05-30
MX349796B (es) 2017-08-11
US20150023940A1 (en) 2015-01-22
WO2010132479A3 (en) 2011-03-31
KR101860294B1 (ko) 2018-07-02
EA201101523A1 (ru) 2012-10-30
EP2429512A2 (en) 2012-03-21
AU2016269471A1 (en) 2016-12-22
US20180355435A1 (en) 2018-12-13
CN102482713B (zh) 2017-06-30
JP2012526555A (ja) 2012-11-01
US9205064B2 (en) 2015-12-08
BRPI1010648A2 (pt) 2016-03-15
KR101829201B1 (ko) 2018-02-19
JP6254979B2 (ja) 2017-12-27
MX2011011958A (es) 2012-02-13
EA201101522A1 (ru) 2012-09-28
SG10201402289VA (en) 2014-07-30
SG175992A1 (en) 2011-12-29
EP2429513A4 (en) 2013-08-14
SG175991A1 (en) 2011-12-29
EP2430194A4 (en) 2013-09-04
CN105287449A (zh) 2016-02-03
CA2761717A1 (en) 2010-11-18
AU2016222515A1 (en) 2016-09-22
JP2012526554A (ja) 2012-11-01
EP2429511A2 (en) 2012-03-21
JP6169846B2 (ja) 2017-07-26
MX2011011942A (es) 2011-12-06
JP6081195B2 (ja) 2017-02-15
CN102482713A (zh) 2012-05-30
JP2012526829A (ja) 2012-11-01
CN102483419B (zh) 2017-12-15
US20160145693A1 (en) 2016-05-26
KR20140014390A (ko) 2014-02-06
EP2429511B1 (en) 2019-02-20
US20110027247A1 (en) 2011-02-03
JP2018048125A (ja) 2018-03-29
IL216298A0 (en) 2012-01-31
JP2015199746A (ja) 2015-11-12
IL216296B (en) 2020-06-30
US20110110914A1 (en) 2011-05-12
US20200157630A1 (en) 2020-05-21
WO2010132440A3 (en) 2011-04-07
JP2017214413A (ja) 2017-12-07
AU2010247750B2 (en) 2016-09-22
AU2016204621A1 (en) 2016-07-21
SG10201402291QA (en) 2014-07-30
JP2017074038A (ja) 2017-04-20
US20110123987A1 (en) 2011-05-26
WO2010132507A3 (en) 2011-03-31
JP2016023189A (ja) 2016-02-08
JP2018021064A (ja) 2018-02-08
IL216295A0 (en) 2012-01-31
US20220081720A1 (en) 2022-03-17
WO2010132502A2 (en) 2010-11-18
CN104825429A (zh) 2015-08-12
CA2763336A1 (en) 2010-11-18
EA201101520A1 (ru) 2012-09-28
CN102483419A (zh) 2012-05-30
SG175993A1 (en) 2011-12-29
CA2763347A1 (en) 2010-11-18
WO2010132502A3 (en) 2011-04-21
JP2017018134A (ja) 2017-01-26
BRPI1010908A2 (pt) 2016-03-15
JP5903734B2 (ja) 2016-04-13
US20210332439A1 (en) 2021-10-28
AU2010247755B2 (en) 2016-09-15
CA2763325A1 (en) 2010-11-18
EP2430455A2 (en) 2012-03-21
AU2010247734B2 (en) 2016-04-14
MX2011011947A (es) 2012-01-30
US20180334721A1 (en) 2018-11-22
MX351083B (es) 2017-09-29
US20110020312A1 (en) 2011-01-27
KR20180056816A (ko) 2018-05-29
WO2010132486A3 (en) 2011-03-03
BRPI1011025A2 (pt) 2016-03-29
JP5903735B2 (ja) 2016-04-13
WO2010132440A2 (en) 2010-11-18
EP2430455A4 (en) 2013-09-04
JP2012526824A (ja) 2012-11-01
AU2010247734A1 (en) 2011-12-15
EA201101519A1 (ru) 2012-10-30
IL216297A0 (en) 2012-01-31
IL216299A0 (en) 2012-01-31
CA2762213A1 (en) 2010-11-18
AU2010247761A1 (en) 2011-12-15
EA034552B1 (ru) 2020-02-19
SG10201402293SA (en) 2014-08-28
SG175994A1 (en) 2011-12-29
CN102481271A (zh) 2012-05-30
WO2010132507A2 (en) 2010-11-18
AU2010247755A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
US11028446B2 (en) Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140812